Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859756 | 0.78 | NPY5R (0.55) | NPY5RDRD3MTNR1AMTNR1BHTR2C | |
| SCHEMBL14685832 | 0.77 | NPY5R (0.50) | NPY5RDRD3MTNR1AMTNR1BHTR2C | |
| SCHEMBL12387508 | 0.76 | MCHR1 (0.38) | DRD3HTR2C | |
| SCHEMBL2310619 | 0.76 | ALDH1A1 (0.37) | HTR2C | |
| Hydrochloric Acid SCHEMBL2309049 | 0.75 | MCHR1 (0.37) | DRD3HTR2C | |
| SCHEMBL5556488 | 0.75 | NPY5R (0.49) | NPY5RDRD3 | |
| SCHEMBL19384067 | 0.73 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2315501 | 0.73 | MCHR1 (0.36) | HTR2C | |
| SCHEMBL4519708 | 0.72 | CHRM2 (0.64) | DRD3MTNR1AMTNR1BCHRM2CHRM1 | |
| SCHEMBL14720161 | 0.70 | RAB9A (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876179-B1 | Thienopyrimidone compounds | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| EP-1876179-B1 | Thienopyrimidone compounds | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20100069362-A1 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069362-A1 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069362-A1 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-1876179-A1 | THIENOPYRIMIDONE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1876179-A1 | THIENOPYRIMIDONE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069362-A1 | Thienopyrimidone compound | MC1R, MC2R, MC5R | NPY5R 25/4885TACR1 51/4885DRD3 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.